Literature DB >> 34956753

Primary Leptomeningeal B-cell Lymphoma in an Immunocompetent Adult: Case Report.

Andrea Calderon-Castro1, Leonardo Enciso2,3, Rafael Tejada-Cabrera4.   

Abstract

Primary leptomeningeal lymphoma (PLML) is a rare disease, comprising less than 1% of all lymphomas. Clinical manifestations include headache, encephalopathy, ataxia, cranial nerve palsy, and myelitis. Diagnosis requires a combination of magnetic resonance images (MRI), cytology, flow cytometry of cerebrospinal fluid (CSF), and an extensive workup to rule out systemic lymphoma. We describe the case of a 49-year-old man who developed subacute onset headache, encephalopathy, and blindness. Whole-body examinations, including a bone marrow trephine biopsy, excluded systemic lymphoma. Brain MRI showed leptomeningeal enhancement. Cytology and flow cytometry of CSF found a clonal B-cell population making a diagnosis of PLML. He began treatment with rituximab and high-dose methotrexate (HD-MTX), with progressive clinical improvement. CSF analysis after two cycles and one intrathecal methotrexate dose was normal. Brain and spinal MRI images plus CSF analysis, along with an extensive workup to exclude systemic lymphoma, are necessary to diagnose PLM. Early treatment with HD-MTX alone or in combination with rituximab improves clinical outcomes.
Copyright © 2021, Calderon-Castro et al.

Entities:  

Keywords:  b-cell lymphoma; flow cytometry; lymphoma; meningeal neoplasms; methotrexate

Year:  2021        PMID: 34956753      PMCID: PMC8674856          DOI: 10.7759/cureus.19619

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  9 in total

Review 1.  Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents.

Authors:  Andrés José María Ferreri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 2.  Primary leptomeningeal central nervous system lymphoma in an immunocompetent adolescent: an unusual presentation.

Authors:  Marc R Jordaan; Sanjay P Prabhu; V Michelle Silvera
Journal:  Pediatr Radiol       Date:  2010-05-13

Review 3.  A systematic approach to the diagnosis of suspected central nervous system lymphoma.

Authors:  Brian J Scott; Vanja C Douglas; Tarik Tihan; James L Rubenstein; S Andrew Josephson
Journal:  JAMA Neurol       Date:  2013-03-01       Impact factor: 18.302

4.  Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

Authors:  Andrés J M Ferreri; Kate Cwynarski; Elisa Pulczynski; Maurilio Ponzoni; Martina Deckert; Letterio S Politi; Valter Torri; Christopher P Fox; Paul La Rosée; Elisabeth Schorb; Achille Ambrosetti; Alexander Roth; Claire Hemmaway; Angela Ferrari; Kim M Linton; Roberta Rudà; Mascha Binder; Tobias Pukrop; Monica Balzarotti; Alberto Fabbri; Peter Johnson; Jette Sønderskov Gørløv; Georg Hess; Jens Panse; Francesco Pisani; Alessandra Tucci; Stephan Stilgenbauer; Bernd Hertenstein; Ulrich Keller; Stefan W Krause; Alessandro Levis; Hans J Schmoll; Franco Cavalli; Jürgen Finke; Michele Reni; Emanuele Zucca; Gerald Illerhaus
Journal:  Lancet Haematol       Date:  2016-04-06       Impact factor: 18.959

Review 5.  Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature.

Authors:  D H Lachance; B P O'Neill; D R Macdonald; K A Jaeckle; T E Witzig; C Y Li; J B Posner
Journal:  Neurology       Date:  1991-01       Impact factor: 9.910

6.  Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report.

Authors:  Jennie W Taylor; Eoin P Flanagan; Brian P O'Neill; Tali Siegal; Antonio Omuro; Lisa Deangelis; Joachim Baehring; Ryo Nishikawa; Fernando Pinto; Marc Chamberlain; Khe Hoang-Xuan; Alberto Gonzalez-Aguilar; Tracy Batchelor; Jean-Yves Blay; Agnieszka Korfel; Rebecca A Betensky; Maria-Beatriz S Lopes; David Schiff
Journal:  Neurology       Date:  2013-10-09       Impact factor: 9.910

7.  Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.

Authors:  Andrés J M Ferreri; Kate Cwynarski; Elisa Pulczynski; Christopher P Fox; Elisabeth Schorb; Paul La Rosée; Mascha Binder; Alberto Fabbri; Valter Torri; Eleonora Minacapelli; Monica Falautano; Fiorella Ilariucci; Achille Ambrosetti; Alexander Roth; Claire Hemmaway; Peter Johnson; Kim M Linton; Tobias Pukrop; Jette Sønderskov Gørløv; Monica Balzarotti; Georg Hess; Ulrich Keller; Stephan Stilgenbauer; Jens Panse; Alessandra Tucci; Lorella Orsucci; Francesco Pisani; Alessandro Levis; Stefan W Krause; Hans J Schmoll; Bernd Hertenstein; Mathias Rummel; Jeffery Smith; Michael Pfreundschuh; Giuseppina Cabras; Francesco Angrilli; Maurilio Ponzoni; Martina Deckert; Letterio S Politi; Jürgen Finke; Michele Reni; Franco Cavalli; Emanuele Zucca; Gerald Illerhaus
Journal:  Lancet Haematol       Date:  2017-10-17       Impact factor: 18.959

Review 8.  Adenosine deaminase inhibition.

Authors:  S Bagheri; A A Saboury; T Haertlé
Journal:  Int J Biol Macromol       Date:  2019-09-11       Impact factor: 6.953

9.  The dubious value of cerebrospinal fluid adenosine deaminase measurement for the diagnosis of tuberculous meningitis.

Authors:  Pieter Ekermans; Adriano Dusé; Jaya George
Journal:  BMC Infect Dis       Date:  2017-01-31       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.